Filing Analysis
Estrella Immunopharma received a notice from Nasdaq stating it is non-compliant with Listing Rule 5620(a) due to failure to hold an annual meeting of shareholders. The company has 45 days to submit a compliance plan and intends to hold the meeting in April 2026.
🚩 Red Flags
- Delisting notice/non-compliance with Nasdaq rules
- Failure to hold mandatory annual shareholder meeting suggests potential administrative or governance issues
📋 Key Facts
- Received notice from Nasdaq on January 7, 2026.
- Non-compliance is due to failure to hold an annual meeting of shareholders (Nasdaq Listing Rule 5620(a)).
- The company has 45 calendar days from the notice date to submit a compliance plan.
- Management plans to convene the annual meeting in April 2026.
- No immediate effect on listing or trading was reported.
Estrella Immunopharma completed a registered direct offering and private placement on January 6, 2026, raising approximately $8.0 million in gross proceeds. The transaction involved the issuance of common stock, pre-funded warrants, and PIPE common warrants to a healthcare-focused institutional investor.
🚩 Red Flags
- Significant potential dilution: The issuance of over 7.5 million PIPE Common Warrants and 1 million pre-funded warrants represents substantial future dilution for existing shareholders.
- Warrant overhang: Large number of warrants exercisable at $1.39 per share may create downward selling pressure upon exercise.
📋 Key Facts
- Gross proceeds from Offerings: approximately $8.0 million (before fees).
- Issued 4,063,290 shares of Common Stock at $1.58 per unit.
- Issued pre-funded warrants to purchase 1,000,000 shares for $0.00001 per share.
- Issued PIPE Common Warrants exercisable for up to 7,594,935 shares at $1.39 per share.
- Placement Agent (Aegis Capital Corp.) to receive a 6.0% cash fee plus expenses.
- Registration Rights Agreement requires filing a resale registration statement within 30 days of closing.
Estrella Immunopharma, Inc. has successfully regained compliance with Nasdaq listing requirements regarding both minimum stockholders' equity and the minimum bid price requirement. The company is no longer in deficiency for these specific matters as of December 11, 2024.
🚩 Red Flags
- Recent history of delisting risk due to minimum bid price and stockholders' equity deficiencies.
📋 Key Facts
- Regained compliance with Nasdaq Listing Rule 5550(b)(1) (Stockholders' Equity Requirement) after market value of listed securities exceeded $35,000,000 for 10 consecutive business days.
- Regained compliance with Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Requirement) as the closing bid price was at or above $1.00 per share for 10 consecutive business days.
- The deficiency periods were noted from November 25, 2024, to December 10, 2024.
- Compliance status for both matters is officially closed as of the December 11, 2024 notification.
Estrella Immunopharma entered into an amendment to its existing Common Stock Purchase Agreement with White Lion Capital, LLC. The amendment extends the agreement term through December 30, 2025, and introduces a 'Rapid Purchase' mechanism for expedited share settlements.
🚩 Red Flags
- Potential for significant dilution due to the $50 million equity capacity.
- The 'Rapid Purchase' mechanism and pricing at the 'lowest traded price' can lead to rapid downward pressure on stock price (death spiral-like characteristics).
- High volume of potential share issuance relative to typical micro-cap liquidity.
📋 Key Facts
- Amendment No. 2 to the Common Stock Purchase Agreement dated April 20, 2023.
- The agreement allows White Lion Capital, LLC to purchase up to $50 million in common stock from time to time.
- Term extension: The expiration date is moved from December 30, 2024, to December 30, 2025.
- Introduction of 'Rapid Purchase' mechanism: Allows for expedited settlement via DWAC on any business day when the stock is not trading OTC.
- Pricing for Rapid Purchases: The lowest traded price of the Company’s common stock on the notice date.
- Volume limitations: Rapid purchases are capped at the lesser of 20% of average daily trading volume or a specific investment limit calculation, though White Lion may waive these.
Estrella Immunopharma, Inc. has announced a change in its fiscal year end from June 30 to December 31, effective immediately. This change is intended to align the company's reporting with the calendar year and streamline accounting processes.
📋 Key Facts
- Board of Directors approved changing the fiscal year end from June 30 to December 31 on November 25, 2024.
- A transition period will occur from July 1, 2024, to December 31, 2024.
- The company expects to file a transition report on Form 10-KT including audited financial statements for the transition period.
Estrella Immunopharma received two deficiency notices from Nasdaq on November 19, 2024: one for failing to meet the minimum stockholders' equity requirement and another for failing to maintain a minimum bid price of $1.00 per share.
🚩 Red Flags
- Delisting notice (Stockholders' Equity Requirement)
- Delisting notice (Minimum Bid Price Deficiency)
- Significant equity shortfall ($746,286 vs $2.5M required)
- Potential for a reverse stock split to avoid delisting
- Failure to meet alternative compliance standards (market value or net income)
📋 Key Facts
- Stockholders' Equity Deficiency: Reported equity of $746,286 as of Sept 30, 2024, which is below the required $2.5 million (Nasdaq Rule 5550(b)(1)).
- Minimum Bid Price Deficiency: Common stock has been below $1.00 for 30 consecutive business days (Nasdaq Rule 5550(a)(2)).
- Equity Compliance Deadline: Must submit a compliance plan by January 3, 2025.
- Bid Price Compliance Deadline: Has 180 days (until May 19, 2025) to regain compliance, with potential for an additional 180-day extension if certain conditions are met.
- Potential Remedy: The company explicitly mentions that a reverse stock split may be necessary to satisfy the bid price requirement.
Estrella Immunopharma, Inc. entered into a consulting agreement with Cofame Investment Management Co. Ltd., a company owned and controlled by the Company's Chairperson and Director, Hong Zhang. The deal involves significant cash payments and a large equity grant.
🚩 Red Flags
- Related-party transaction involving the Chairperson and Director (Hong Zhang).
- Significant equity component (up to 1,000,000 shares) granted to an entity controlled by a director.
- Potential for dilution of existing shareholders through the large stock option grant.
📋 Key Facts
- Consulting Agreement effective November 1, 2024, with Cofame Investment Management Co. Ltd.
- Cofame is owned and controlled by Ms. Hong Zhang (Chairperson/Director).
- Upfront cash payment of $55,000 to the Consultant.
- Annual consulting fee of $220,000, payable at least monthly.
- Equity grant: Option to purchase up to 1,000,000 shares of common stock under the 2023 Omnibus Incentive Plan.
- Vesting schedule for equity: 25% on August 1, 2025; remaining 75% over 36 months contingent on continued services.
Estrella Immunopharma, Inc. announced a new employment agreement with Dr. Cheng Liu as Director, President, and Chief Executive Officer, effective November 1, 2024.
📋 Key Facts
- Dr. Cheng Liu appointed as Director, President, and CEO effective Nov 1, 2024.
- Annual base salary set at $250,000.
- Eligible for annual cash bonuses based on financial, operational, and individual performance metrics.
- Eligible for annual grants of incentive equity awards.
- Employment is 'at will' with severance provisions detailed in the agreement.
Estrella Immunopharma, Inc. announced the appointment of Ms. Hong Zhang as Chairperson and a member of the Board of Directors, effective August 14, 2024. This move expands the Board from five to six members and involves potential future related-party consulting arrangements.
🚩 Red Flags
- Potential related-party transaction: The company is negotiating a consulting agreement with a firm owned by the newly appointed Chairperson.
- Future disclosure requirement: The company must file an amendment within four business days once terms of the potential consulting agreement are finalized.
📋 Key Facts
- Ms. Hong Zhang appointed as Chairperson and Director on August 14, 2024.
- Board size increased from five to six directors.
- Dr. Cheng Liu (CEO) will remain a director but is no longer the sole Chairperson.
- Ms. Zhang to receive $5,000/quarter for director service and $2,500/quarter as Chairperson.
- The company is negotiating a Consulting Agreement with a company owned by Ms. Zhang regarding strategic initiatives in Asia.
Estrella Immunopharma announced the dosing of the first patient in its Phase I/II clinical trial for EB103, an autologous T-cell therapy targeting relapsed/refractory B-cell Non-Hodgkin’s Lymphomas. This is a standard operational update regarding clinical trial progression.
📋 Key Facts
- First patient dosed in Phase I/II clinical trial for EB103 on July 31, 2024.
- EB103 is an autologous T-cell therapy.
- Target indication: adult patients with relapsed/refractory B-cell Non-Hodgkin’s Lymphomas.
Estrella Immunopharma, Inc. completed a merger with its wholly-owned subsidiary, Estrella Biopharma, Inc., effective June 30, 2024. The transaction was designed to simplify the corporate structure and streamline financial reporting.
📋 Key Facts
- Merger between parent (Estrella Immunopharma, Inc.) and wholly-owned subsidiary (Estrella Biopharma, Inc.).
- Effective date of merger: June 30, 2024, at 11:59 PM ET.
- The merger was approved via unanimous written consent of the Board of Directors.
- Company assumed all assets, liabilities, and obligations of the subsidiary.
- No changes to management, board composition, or ownership resulted from the merger.
Estrella Immunopharma entered into an amendment to a Statement of Work with its controlling shareholder, Eureka Therapeutics, Inc. The amendment clarifies termination and suspension compensation terms regarding clinical trial services for the EB103 anti-CD19 ARTEMIS® program.
🚩 Red Flags
- Related-party transaction involving the controlling shareholder (Eureka Therapeutics, Inc.).
- The amendment specifically addresses termination/suspension liabilities, which may indicate a need for more flexible exit terms from the parent company's services.
📋 Key Facts
- Amendment No. 1 to SOW #001 was entered into on May 13, 2024, effective March 4, 2024.
- The agreement is between Estrella Immunopharma (Company), its subsidiary Estrella Biopharma, and Eureka Therapeutics, Inc. (Controlling Shareholder).
- The SOW relates to services performed by Eureka for the EB103 anti-CD19 ARTEMIS® clinical trial.
- Amendment clarifies that if Estrella terminates/suspends the engagement, it is only liable for: (i) milestones achieved prior to notice, (ii) documented pass-through costs incurred prior to notice, and (iii) third-party commitments made by Eureka on behalf of Estrella prior to notice.
Estrella Immunopharma, Inc. filed an 8-K to furnish an investor presentation via its website under Regulation FD. The filing does not contain material financial changes or corporate structural updates.
📋 Key Facts
- Company posted an investor presentation to its website (www.estrellabio.com) on April 10, 2024.
- The presentation is intended for use in meetings with investors and analysts.
- The filing was made under Item 7.01 (Regulation FD Disclosure).
- The information provided in the exhibit is furnished rather than filed, limiting liability under Section 18 of the Exchange Act.
Estrella Immunopharma, Inc. provided details regarding the timing and method of its planned $1,000,000 common stock repurchase program. The company intends to use existing cash reserves to buy shares on the open market over the next 12 months.
🚩 Red Flags
- No immediate red flags identified in this specific disclosure; however, share repurchases by micro-cap companies can sometimes be used to artificially support stock prices if not conducted strictly under Rule 10b-18.
📋 Key Facts
- The company plans to repurchase up to $1,000,000 of its common stock.
- Repurchases will be conducted in the open market at prevailing prices.
- The plan is designed to comply with Rule 10b5-1 and Rule 10b-18 of the Securities Exchange Act.
- Funding for the repurchase will come from existing cash reserves.
- The timeframe for the repurchases is within the next 12 months.
Estrella Immunopharma entered into a Statement of Work (SOW) with its controlling shareholder, Eureka Therapeutics, for clinical trial services related to the Phase I/II trial of EB103. The agreement involves significant milestone-based payments totaling $33 million plus expenses.
🚩 Red Flags
- Related-party transaction: The service provider (Eureka) is the company's controlling shareholder.
- Significant liquidity requirement: The company must secure financing to meet substantial milestone payments ($3.5M immediate, $1.5M deposit, and ongoing patient dosing costs).
- Potential for conflict of interest regarding pricing and service terms in a controlled transaction.
📋 Key Facts
- Agreement date: March 4, 2024.
- Total milestone fees: $33,000,000 (excluding pass-through costs and expenses).
- Initial invoice of $3.5 million due upon execution for study initiation and site activation.
- Required deposit of $1.5 million prior to patient dosing phase.
- Estimated milestone timeline: 6 patients by end of 2024; remaining 14 patients by end of 2025; study close-out by end of 2025.
- Eureka Therapeutics is the controlling shareholder of Estrella Immunopharma.
Estrella Immunopharma, Inc. has dismissed its independent auditor, Marcum LLP, and appointed Macias Gini & O’Connell, LLP (MGO) as its new accounting firm effective January 30, 2024.
🚩 Red Flags
- Auditor change (dismissal of Marcum LLP).
- Previous auditor issued a 'going concern' warning in the FY 2023 report.
- Company is an emerging growth company, often associated with higher volatility and less stringent reporting requirements.
📋 Key Facts
- Dismissal of Marcum LLP by the Board and Audit Committee on January 30, 2024.
- Appointment of Macias Gini & O’Connell, LLP (MGO) as the new auditor for fiscal year ending June 30, 2024.
- The previous auditor's report for FY ended June 30, 2023, included an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern.
- The company states there were no disagreements with Marcum LLP regarding accounting principles, practices, or auditing scope prior to dismissal.
Estrella Immunopharma, Inc. announced that its board of directors has authorized a share repurchase program of up to $1 million of common stock.
📋 Key Facts
- Board authorization for share repurchases up to $1 million of common stock.
- Repurchase timing and method are discretionary and not a binding commitment.
- Announcement date: January 30, 2024.